脂蛋白相关磷脂酶A2与冠心病患者左心功能的相关性及厄贝沙坦干预的作用分析

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (34 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the analysis of lipoprotein associated phospholipase A2(lipoprotein-associated phospholipase A2,Lp-PLA2)and the correlation of left heart function in patients with coronary heart disease (CHD),and explore he sand and the effect of intervention in patients with coronary heart disease(CHD).Methods A total of 116 cases of patients with coronary heart disease (CHD)and 50 cases of healthy volunteers with physical examination in the hospital from January 2016 to March 2018 were selected and set to coronary heart disease group and the control group respectively.The level of plasma Lp-PLA2 expression was measured and the level of plasma Lp-PLA2 expression was compared between the coronary heart disease group and the control group,and the left cardiac ejection fraction of the two groups was compared.According to the left cardiac ejection fraction,the patients in the coronary heart disease group were divided into left heart dysfunction group and normal left heart function group.The plasma Lp-PLA2 expression level of patients with different left heart function was compared,and the correlation between plasma Lp-PLA2 expression level and left heart function of patients with coronary heart disease was analyzed.Irbesartan drug intervention was applied to patients with coronary heart disease.The left ventricular ejection fraction and plasma Lp-PLA2 level were compared before and after treatment.Results The expression level of plasma Lp-PLA2 in the CHD group was higher than that in the control group (P＜0.05).The left cardiac ejection fraction in the CHD group was lower than the control group (P＜0.05).The expression level of plasma Lp-PLA2 in the left cardiac dysfunction group was higher than that in the left cardiac function group (P＜0.05),and the expression level of plasma Lp-PLA2 was negatively correlated with the left cardiac function(r=-0.783,P＜0.05).After treatment with irbesartan,the left cardiac ejection fraction of the patients with coronary heart disease was higher than that before treatment(P＜0.05),and the plasma Lp-PLA2 expression level was lower than that before treatment(P＜0.05).Conclusion The level of plasma Lp-PLA2 expression in patients with coronary heart disease is generally up-regulated,and the level of plasma Lp-PLA2 expression can reflect the left heart function of patients with coronary heart disease,and the intervention by irbesartan can effectively improve the left heart function of the patients,and reduce the level of Lp-PLA2 expression in plasma.

Key words： Coronary heart disease Lipoprotein associated phospholipase A2 Left ventricular function Correlation Irbesartan

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HE Ding-yang
	ZHAO Xin-sheng
	HUANG Chuang-jie

Cite this article:

HE Ding-yang,ZHAO Xin-sheng,HUANG Chuang-jie. The correlation between lp-pla2 and left cardiac function in patients with coronary heart disease and the effect of erbesartan intervention[J]. 中国当代医药, 2018, 25(25): 72-74.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I25/72

[1]	Otunctemur A，Sahin S，Ozbek E，et al.Lipoprotein-associated phospholipase A2 levels are associated with erectile dysfunction in patients without known coronary artery disease[J].Andrologia，2015，47（6）：706-710.
[2]	张彤格，贾玫.脂蛋白相关性磷脂酶A2与冠心病相关性研究进展[J].中华检验医学杂志，2015，38（7）：493-497.
[3]	秦召敏，沈钦海，孔瑞雪，等.血浆 Lp-PLA2、MIP-1α、GPⅠb与冠心病冠状动脉粥样硬化病变严重程度的关系[J].重庆医学，2017，46（24）：3411-3413.
[4]	李明.血清Lp-PLA2、hs-CRP和D-二聚体在冠心病患者冠脉病变程度中的评估价值[J].重庆医学，2015，44（9）：1215-1217，1220.
[5]	郑迪，付瑞雪，李文华，等.脂蛋白相关磷脂酶A2、抗凝血酶Ⅲ与冠脉病变程度的关系[J].实用医学杂志，2017，33（16）：2721-2724.
[6]	程清.脂蛋白相关磷脂酶A2和同型半胱氨酸水平与动脉粥样硬化性心脑血管疾病关系的研究[J].检验医学，2015，30（1）：40-43.
[7]	胡蓉，方先松，江丽霞，等.冠心病患者血清Lp－PLA2及hs－CRP水平与冠状动脉粥样硬化易损斑块的相关性[J].中国老年学杂志，2015，35（1）：74-75.
[8]	范艳平，李海滨，谭清武，等.人血浆脂蛋白相关磷脂酶A2在冠状动脉粥样硬化中的研究进展[J].临床误诊误治，2016，29（6）：110-113.
[9]	吕雪莹.血浆脂蛋白相关磷脂酶A-2在冠状动脉疾病中应用新进展[J].中国循环杂志，2017，32（2）：190-193.
[10]	郭梅，罗涛，吴园，等.血浆脂蛋白相关磷脂酶A2在冠脉病变中的临床应用价值[J].国际检验医学杂志，2016，37（1）：28-30.
[11]	杜文涛，石雪，乔艳，等.脂蛋白相关磷脂酶 A2与冠脉斑块严重程度的关系及不同剂量瑞舒伐他汀对其浓度的影响[J].中国药师，2016，19（6）：1126-1129.
[12]	苗兴妮，尹德录，赵新华，等.急性冠状动脉综合征患者脂蛋白相关磷脂酶A2的预测价值[J].中国循环杂志，2017，32（12）：1172-1176.
[13]	郭瑄，张春艳，王聪霞，等.非ST段抬高 ACS患者血浆sCD40L和Lp-PLA2水平对冠脉病变程度及危险性的评估价值[J].西安交通大学学报（医学版），2016，37（3）：322-326.
[14]	孙旭，贾志，梁海青，等.急性冠脉综合征患者血浆脂蛋白相关磷脂酶A2与GRACE积分的关系[J].山东医药，2015，55（8）：43-45.
[15]	熊卿圆，曾赤佳，岑锦明，等.不同类型冠状动脉粥样硬化性心脏病患者血浆脂蛋白相关磷脂酶A2水平变化的临床意义[J].中国现代医学杂志，2015，25（29）：78-82.